Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga
{"title":"为阿尔茨海默病及相关痴呆症研究建立多生物标志物低容量面板基准","authors":"Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga","doi":"10.1002/alz.14413","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>We tested the novel technology NUcleic acid Linked Immuno-Sandwich Assay (NULISA) in the dementia research setting.</li>\n \n <li>NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume.</li>\n \n <li>Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA.</li>\n \n <li>In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis.</li>\n \n <li>NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14413","citationCount":"0","resultStr":"{\"title\":\"Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research\",\"authors\":\"Laura Ibanez, Menghan Liu, Aleksandra Beric, Jigyasha Timsina, Pat Kohlfeld, Kristy Bergmann, Joey Lowery, Nick Sykora, Brenda Sanchez-Montejo, Will Brock, John P. Budde, Randall J. Bateman, Nicolas Barthelemy, Suzanne E. Schindler, David M. Holtzman, Tammie L. S. Benzinger, Chengjie Xiong, Rawan Tarawneh, Krista Moulder, John C. Morris, Yun Ju Sung, Carlos Cruchaga\",\"doi\":\"10.1002/alz.14413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>We tested the novel technology NUcleic acid Linked Immuno-Sandwich Assay (NULISA) in the dementia research setting.</li>\\n \\n <li>NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume.</li>\\n \\n <li>Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA.</li>\\n \\n <li>In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis.</li>\\n \\n <li>NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 2\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14413\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14413\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14413","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research
INTRODUCTION
In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno-Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.
METHODS
We compared AD-relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.
RESULTS
CSF measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform.
DISCUSSION
The NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.
Highlights
We tested the novel technology NUcleic acid Linked Immuno-Sandwich Assay (NULISA) in the dementia research setting.
NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume.
Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p-tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA.
In plasma, p-tau217 performance is similar to that reported with other technologies when predicting amyloidosis.
NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
